Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
Lim, Ee Tuan;
Petzold, Axel;
Leary, Siobhan M;
Altmann, Daniel R;
Keir, Geoff;
Thompson, Ed J;
Miller, David H;
Thompson, Alan J;
Giovannoni, Gavin;
(2004)
Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a.
Journal of negative results in biomedicine, 3 (1).
4-.
ISSN 1477-5751
DOI: https://doi.org/10.1186/1477-5751-3-4
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled trial of Interferon beta-1a in subjects with PPMS. The key questions were whether S100B levels were associated with either disability or MRI findings in primary progressive MS and whether Interferon beta-1a has an effect on their S100B levels. Serial serum S100B levels were measured using an ELISA method. The results demonstrated that serum S100B is not related to either disease progression or MRI findings in subjects with primary progressive MS given Interferon beta-1a. Furthermore there is no correlation between S100B levels and the primary and secondary outcome measures.